BRCAness: Finding the achilles heel in ovarian cancer

Oncologist

Volumn 17, Issue 7, 2012, Pages 956-962

  Rigakos, Georgios ^a   Razis, Evangelia ^a  

^a HYGEIA HOSPITAL   (Greece)

Author keywords

BRCA1 2; BRCAness; Ovarian cancer; PARP inhibitors; Synthetic lethality

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEDIRANIB; CHECKPOINT KINASE 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; GEMCITABINE; INIPARIB; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; RAD51 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

APOPTOSIS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DNA DAMAGE; DNA METHYLATION; EMSY GENE; EXCISION REPAIR; FAMILIAL CANCER; GENE; GENE MUTATION; GENE SILENCING; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINATION REPAIR; REVIEW; SOMATIC MUTATION;

DNA REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS;

EID: 84864053120     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0028     Document Type: Review

References (98)

1. Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001;3:27-32.
2. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265.
3. Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346-1352.
4. Aida H, Takakuwa K, Nagata H et al. Clinical features of ovarian cancer in Japanese women with germline mutations of BRCA1. Clin Cancer Res 1998;4:235-240.
5. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-1416.
6. Gourley C, Michie CO, Roxburgh P et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: An extension of the ovarian BRCAness phenotype. J Clin Oncol 2010;28: 2505-2511.
7. Jóhannsson OT, Ranstam J, Borg A et al. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 1998;16(2):397-404.
8. Pharoah PD, Easton DF, Stockton DL et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999;59:868-871.
9. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 2008;26: 20-25.
10. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004; 4:814-819.
11. Tan DS, Rothermundt C, Thomas K et al. "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008;26:5530-5536.
12. Foster KA, Harrington P, Kerr J et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996;56:3622-3625.
13. Baldwin RL, Nemeth E, Tran H et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 2000;60:5329-5333.
14. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92: 564-569.
15. Geisler JP, Hatterman-Zogg MA, Rathe JA et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-67.
16. Hennessy BT, Timms KM, Carey MS et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ri-bose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-3576.
17. Hilton JL, Geisler JP, Rathe JA et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-1406.
18. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-323.
19. Wang C, Horiuchi A, Imai T et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-223.
20. Merajver SD, Pham TM, Caduff RF et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995;9:439-443.
21. Futreal PA, Liu Q, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-122.
22. Lancaster JM, Wooster R, Mangion J et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238-240.
23. Bell D, Berchuck A, Birrer M et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
24. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-357.
25. Chiang JW, Karlan BY, Cass L et al. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006;101:403-410.
26. Beckmann MW, Picard F, An HX et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 1996;73:1220-1226.
27. Brown LA, Irving J, Parker R et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006;100:264-270.
28. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-535.
29. Cousineau I, Belmaaza A. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: Implications for chromosomal instability/ recombination syndromes as checkpoint diseases. Mol Genet Genomics 2011;285:325-340.
30. D'Andrea AD. The Fanconi anemia/BRCA signaling pathway: Disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290-292.
31. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-574.
32. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-170.
33. Skytte AB, Waldstrøm M, Rasmussen AA, et al. Identification of BRCA1-deficient ovarian cancers. Acta Obstet Gynecol Scand 2011;90:593-599.
34. Weberpals JI, Tu D, Squire JA et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: An NCIC CTG OV. 16 correlative study. Ann Oncol 2011;22:2403-2410.
35. Vollebergh MA, Lips EH, Nederlof PM et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-1570.
36. Soslow RA, Han G, Park KJ et al Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25:625-636.
37. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21: 134-147.
38. Jazaeri AA, Yee CJ, Sotiriou C et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94: 990-1000.
39. Konstantinopoulos PA, Spentzos D, Karlan BY et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-3561.
40. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
41. Zweemer RP, Shaw PA, Verheijen RM et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999;52:372-375.
42. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;31:961-967.
43. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668.
44. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-4850.
45. Bhattacharyya A, Ear US, Koller BH et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903.
46. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-2195.
47. Yang D, Khan S, Sun Y et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-1565.
48. Lotti LV, Ottini L, D'Amico C et al. Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 2002;35:193-203.
49. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res 2001;61:7713-7718.
50. Lafarge S, Sylvain V, Ferrara M et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-6606.
51. Harkin DP, Bean JM, Miklos D et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-586.
52. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97: 813-820.
53. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-1291.
54. Egawa C, Miyoshi Y, Takamura Y et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001; 95:255-259.
55. Page C, Lin HJ, Jin Y, et al. Overexpression of Akt/ AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000;20:407-416.
56. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002; 20:845-853.
57. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003;22:2396-2404.
58. Quinn JE, James CR, Stewart GE et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-7420.
59. Hartwell LH, Szankasi P, Roberts CJ et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-1068.
60. Iglehart JD, Silver DP. Synthetic lethality-A new direction in cancer-drug development. N Engl J Med 2009;361:189-191.
61. Dobzhansky T. Genetics of natural populations: Recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946;31:269-290.
62. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann Oncol 2011;22:268-279.
63. Farmer H, McCabe N, Lord CJ et al. Targeting the DNArepair defect in BRC Amutant cells as a therapeutic strategy. Nature 2005;434:917-921.
64. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917.
65. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
66. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-2519.
67. Menear KA, Adcock C, Barlter R et al. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-f luorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-6591.
68. Tutt A, Robson M, Garber JE et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-244.
69. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010; 376:245-251.
70. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-8115.
71. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-861.
72. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29:1007.
73. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012;18:510-523.
74. Patel AG, De Lorenzo S, Flatten K, et al. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012;18:1655-1662.
75. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-379.
76. Telli ML. PARP inhibitors in cancer: Moving beyond BRCA. Lancet Oncol 2011;12:827-828.
77. Zorn KK. PARP inhibition in epithelial ovarian cancer: High hopes undergo a reality check. Oncology 2012;26:1-11.
78. Ang J, Yap TA, Fong P et al. Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). J Clin Oncol 2010;28:5041.
79. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-1120.
80. Swisher EM, Sakai W, Karlan BY et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008;68: 2581-2586.
81. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-3015.
82. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-1115.
83. Yap TA, Sandhu SK, Carden CP et al. Poly(ADPribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011;61:31-49.
84. Gabra H. Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: Teaching old dogs new tricks? Discov Med 2009;8(42):140-144.
85. Lord CJ, McDonald S, Swift S et al. A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008;7:2010-2019.
86. Turner NC, Lord CJ, Iorns E et al A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008;27:1368-1377.
87. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010;28:e563-e564.
88. Mukhopadhyay A, Elattar A, Cerbinskaite A et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADPribose) polymerase inhibitors. Clin Cancer Res 2010;16: 2344-2351.
89. Kennedy RD, Chen CC, Stuckert P et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007;117:1440-1449.
90. Williamson CT, Muzik H, Turhan AG et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010;9:347-357.
91. Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-322.
92. Puc J, Keniry M, Li H et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005;7:193-204.
93. Wang Z, Ahmad A, Li Y et al. Forkhead box M1 transcription factor: A novel target for cancer therapy. Cancer Treat Rev 2010;36:151-156.
94. Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 2007;27:1007-1016.
95. Chan N, Pires IM, Bencokova Z et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010;70:8045-8054.
96. Chan N, Koritzinsky M, Zhao H et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68:605-614.
97. Bindra RS, Gibson SL, Meng A et al. Hypoxiainduced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005;65:11597-11604.
98. Meng AX, Jalali F, Cuddihy A et al. Hypoxia down-regulates DNA double-strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005;76:168-176.